Virtu Financial’s ImmunityBio IBRX Stock Holding History

Virtu Financial’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$593K	Sell	67,774 -194,524	-74%	-$1.47M	0.02%	474
2026 Q1	$2.01M	Buy	+262,298	New	+$1.8M	0.08%	154
2024 Q4	–	Sell	-13,608	Closed	-$51K	–	1764
2024 Q3	$51K	Buy	+13,608	New	+$63K	﹤0.01%	1006
2024 Q2	–	Sell	-11,285	Closed	-$61K	–	1555
2024 Q1	$61K	Sell	11,285 -49,184	-81%	-$223K	﹤0.01%	991
2023 Q4	$304K	Buy	+60,469	New	+$190K	0.02%	601
2022 Q2	–	Sell	-13,190	Closed	-$74K	–	1789
2022 Q1	$74K	Sell	13,190 -17,060	-56%	-$105K	0.01%	1041
2021 Q4	$184K	Buy	30,250 +10,123	+50%	+$76.1K	0.02%	866
2021 Q3	$196K	Buy	+20,127	New	+$221K	0.02%	923
2021 Q2	–	Sell	-22,195	Closed	-$527K	–	1758
2021 Q1	$527K	Buy	+22,195	New	+$575K	0.04%	498
2019 Q3	–	Sell	-21,596	Closed	-$22K	–	1587
2019 Q2	$22K	Buy	+21,596	New	+$24.9K	﹤0.01%	1337
2018 Q4	–	Sell	-10,305	Closed	-$38K	–	1741
2018 Q3	$38K	Buy	+10,305	New	+$32.6K	﹤0.01%	1337
2018 Q2	–	Sell	-46,313	Closed	-$180K	–	2214
2018 Q1	$180K	Buy	+46,313	New	+$203K	0.01%	1401

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Virtu Financial's IBRX Position: Q2 2026 in Review

Virtu Financial reduced its ImmunityBio (IBRX) stake by 74% in Q2 2026, selling an estimated $1.47M and leaving 67,774 shares worth $593K. The position accounts for 0.02% of the portfolio, ranked #474.

Virtu Financial first reported a position in IBRX in Q1 2018 and has held it in 12 quarters since. The position peaked at $2.01M in Q1 2026. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Virtu Financial held 67,774 shares of ImmunityBio worth $593K as of Q2 2026.
Virtu Financial sold 194,524 ImmunityBio shares in Q2 2026, an estimated $1.47M.
ImmunityBio made up 0.02% of Virtu Financial's portfolio in Q2 2026, its #474 holding.
Virtu Financial first reported a position in ImmunityBio in Q1 2018 and has held it in 12 quarters since.
Virtu Financial's ImmunityBio position peaked at $2.01M in Q1 2026.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.